Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer

• Status: Completed
• Trial end date: 2015-08-03
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Oklahoma
• Collaborator: Genentech, Inc.
• Treatments: Bevacizumab; Cisplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Patients with stage II and III epithelial ovarian carcinoma, primary peritoneal carcinoma, or ovarian carcinosarcoma.

• Adequate bone marrow, renal, and hepatic function

• Patients must be entered no more than twelve weeks postoperatively

Exclusion Criteria:

• Patients with epithelial ovarian carcinoma of low malignant potential (borderline carcinomas).

• Stage IV or suboptimally debulked disease following primary cytoreductive surgery

• Patients who have received prior radiotherapy or chemotherapy.